Accelerating Policy Decisions to Adopt Type b Vaccine: A Global, Multivariable Analysis

English version České info

Background:
Adoption of new and underutilized vaccines by national immunization programs is an essential step towards reducing child mortality. Policy decisions to adopt new vaccines in high mortality countries often lag behind decisions in high-income countries. Using the case of Haemophilus influenzae type b (Hib) vaccine, this paper endeavors to explain these delays through the analysis of country-level economic, epidemiological, programmatic and policy-related factors, as well as the role of the Global Alliance for Vaccines and Immunisation (GAVI Alliance).

Methods and Findings:
Data for 147 countries from 1990 to 2007 were analyzed in accelerated failure time models to identify factors that are associated with the time to decision to adopt Hib vaccine. In multivariable models that control for Gross National Income, region, and burden of Hib disease, the receipt of GAVI support speeded the time to decision by a factor of 0.37 (95% CI 0.18–0.76), or 63%. The presence of two or more neighboring country adopters accelerated decisions to adopt by a factor of 0.50 (95% CI 0.33–0.75). For each 1% increase in vaccine price, decisions to adopt are delayed by a factor of 1.02 (95% CI 1.00–1.04). Global recommendations and local studies were not associated with time to decision.

Conclusions:
This study substantiates previous findings related to vaccine price and presents new evidence to suggest that GAVI eligibility is associated with accelerated decisions to adopt Hib vaccine. The influence of neighboring country decisions was also highly significant, suggesting that approaches to support the adoption of new vaccines should consider supply- and demand-side factors.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Accelerating Policy Decisions to Adopt Type b Vaccine: A Global, Multivariable Analysis. PLoS Med 7(3): e32767. doi:10.1371/journal.pmed.1000249
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000249

Souhrn

Zdroje

1. World Health Organization, UNICEF, World Bank 2009 State of the world's vaccines and immunizations Geneva World Health Organization Available: http://www.who.int/immunization/sowvi/en/. Accessed 14 February 2010

2. WattJP

WolfsonLJ

O'BrienKL

HenkleE

Deloria-KnollM

2009 Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates. Lancet 374 903 911

3. World Health Organization 2006 WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 81 445 452

4. WattJP

LevineOS

SantoshamM

2003 Global reduction of Hib disease: What are the next steps? J Pediatr 1436 Suppl S163 87

5. AdegbolaRA

SeckaO

LahaiG

Lloyd-EvansN

NjieA

2005 Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 366 144 150

6. BaquiAH

El ArifeenS

SahaSK

PerssonL

ZamanK

2007 Effectiveness of Haemophilus influenzae type b conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: A case-control study. Pediatr Infect Dis J 26 565 571

7. LewisRF

KisakyeA

GessnerBD

DukuC

OdipioJB

2008 Action for child survival: Elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ 86 292 301

8. O'LoughlinR

HajjehR

Hib Initiative 2008 Worldwide introduction and coverage of Haemophilus influenzae type b conjugate vaccine. Lancet Infect Dis 8 736

9. MillerMA

FlandersWD

2000 A model to estimate the probability of hepatitis B- and Haemophilus influenzae type b-vaccine uptake into national vaccination programs. Vaccine 18 2223 2230

10. Danovaro-HollidayMC

GarciaS

de QuadrosC

TambiniG

AndrusJK

2008 Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med 5 e87 doi:10.1371/journal.pmed.0050087

11. WengerJD

DiFabioJ

LandaverdeJM

LevineOS

GaafarT

1999 Introduction of Hib conjugate vaccines in the non-industrialized world: Experience in four ‘newly adopting’ countries. Vaccine 18 736 742

12. DeRoeckD

ClemensJD

NyameteA

MahoneyRT

2005 Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23 2762 2774

13. MuniraSL

FritzenSA

2007 What influences government adoption of vaccines in developing countries? A policy process analysis. Soc Sci Med 65 1751 1764

14. RossiIA

ZuberPL

DumolardL

WalkerDG

WattJ

2007 Introduction of Hib vaccine into national immunization programmes: A descriptive analysis of global trends. Vaccine 25 7075 7080

15. GauriV

KhaleghianP

2002 Immunization in developing countries: its political and organizational determinants. World Development 30 2109-2110-2130

16. World Health Organization 2008 Immunization surveillance, assessment and monitoring: Data, statistics and monitoring. Available: http://www.who.int/immunization_monitoring/data/en/. Accessed 3 November 2009

17. The World Bank 2008 World development indicators online. Available: http://publications.worldbank.org/WDI/. Accessed 3 November 2009

18. MarshallMG

JaggersK

2008 Polity IV project: Political regime characteristics and transitions, 1800–2007. Available: http://www.systemicpeace.org/polity/polity4.htm. Accessed 3 November 2009

19. World Health Organization 2008 Choosing interventions that are cost-effective (WHO-CHOICE). Available: http://www.who.int/choice/en/. Accessed 3 November 2009

20. British Medical Association 2008 British national formulary. Available: http://bnf.org/bnf/. Accessed 3 November 2009

21. Australian Government Department of Health and Ageing 2008 National immunisation programme schedule. Available: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips2. Accessed 3 November 2009

22. UNICEF 2008 Vaccine projections. Available: http://www.unicef.org/supply/index_7991.html. Accessed 3 November 2009

23. Centers for Disease Control and Prevention 2008 CDC vaccine price list. Available: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm. Accessed 3 November 2009

24. Pan American Health Organization 2008 Revolving fund. Available: http://www.paho.org/english/hvp/hvi/revol_fund.htm. Accessed 3 November 2009

25. PokornM

KopacS

NeubauerD

CizmanM

2001 Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia. Vaccine 19 3600 3605

26. GarpenholtO

SilfverdalSA

LevinLA

1998 Economic evaluation of general childhood vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 30 5 10

27. SoltaniMS

BchirA

AmriF

GueddicheN

SfarT

2005 Epidemiology of Haemophilus influenzae meningitis in Tunisia. East Mediterr Health J 11 14 27

28. [Anonymous] 1998 Global programme for vaccines and immunization (GPV). the WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 73 64 68

29. GAVI Alliance 2008 Who can apply? Available: http://www.gavialliance.org/support/who/index.php. Accessed 03 November 2009

30. KnollMD

O'BrienKL

HenkleE

LeeE

WattJP

2009 Global literature review of Haemophilus influenzae type b and streptococcus pneumoniae invasive disease among children less than 5 years of age 1980–2005 Geneva World Health Organization

31. WiddusR

1999 Introduction of vaccines into the third world. C R Acad Sci III 32 999 1010

32. BrooksA

CuttsFT

JusticeJ

WaltG

1999 Policy study of factors influencing the adoption of new and underutilized vaccines in developing countries Washington USAID

33. WeiLJ

1992 The accelerated failure time model: A useful alternative to the Cox regression model in survival analysis. Stat Med 11 1871 1879

34. WeibullW

1951 A statistical distribution function of wide applicability. J Appl Mech 13 293 297

35. AkaikeH

1974 A new look at the statistical model identification. Automatic Control, IEEE Transactions 19 716 723

36. ClevesM

GouldW

GutierrezR

MarchenkoY

2008 An introduction to survival analysis using Stata College Station, TX Stata Press

37. AndrusJK

SherrisJ

FitzsimmonsJW

KaneMA

AguadoMT

2008 Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 26 Suppl 10 K87 92